John L. Higgins - Nov 17, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Executive Officer, Director
Signature: /s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins
Stock symbol: LGND
Transactions as of: Nov 17, 2022
Transactions value $: -$655,373
Form type: 4
Date filed: 11/21/2022, 06:04 PM
Previous filing: Nov 3, 2022
Next filing: Dec 1, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Sale	-$783K	-10K	-2.34%	$78.32	417K	Nov 17, 2022	Direct	F1
transaction	LGND	Common Stock	Options Exercise	$128K	+10K	+2.4%	$12.78^*	427K	Nov 18, 2022	Direct

Showing 1 to 2 of 2 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LGND	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-10K	-19.87%	$0.00	40.3K	Nov 18, 2022	Common Stock	10K	$12.78	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 22, 2022, in accordance with Rule 10b5-1.
F2	Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The original date of grant was 02/15/13.